Refractoriness to rituximab monotherapy in a child with relapsed/refractory Burkitt non-Hodgkin lymphoma

Pediatric Hematology and Oncology

Volumn 23, Issue 1, 2006, Pages 25-31

  Okur, F Visal ^a   Oguz, Aynur ^a   Karadeniz, Ceyda ^a   Citak, Caglar ^a   Poyraz, Aylar ^a   Boyunaga, Oznur ^a  

^a GAZI UNIVERSITY   (Turkey)

Author keywords

Burkitt NHL; Children; Rituximab

Indexed keywords

RITUXIMAB;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW METASTASIS; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INVASION; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CASE REPORT; CYTOREDUCTIVE SURGERY; DISEASE COURSE; HIGH RISK PATIENT; HUMAN; KIDNEY METASTASIS; LUNG LOBECTOMY; MALE; MEDIASTINUM; MONOTHERAPY; NONHODGKIN LYMPHOMA; PRESCHOOL CHILD; REFRACTORY PERIOD; THORACOTOMY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW NEOPLASMS; BURKITT LYMPHOMA; CHILD; DRUG RESISTANCE, NEOPLASM; FATAL OUTCOME; HUMANS; KIDNEY NEOPLASMS; MALE; MEDIASTINAL NEOPLASMS; NEOPLASM INVASIVENESS; PALLIATIVE CARE; RECURRENCE; REMISSION INDUCTION;

EID: 28844499888     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.1080/08880010500313298     Document Type: Article

References (25)

1. Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma hva similar excellent outcome when treated wih the same chemotherapy regimen. J Clin Oncol. 1996;14:925-934.
2. Patte C, Philip T, Rodary C, et al. High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with short intensive polychemotherapy; results from the French Pediatric Oncology Society of a randomized trial of 216 children. J Clin Oncol. 1991;9:123-132.
3. Patte C, Auperin A, Michon J, et al. The Societe Francaise d'Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphoma and L3 leukemia. Blood. 2001;97:33700-3379.
4. Soussian C, Patte C, Ostronoff M, et al. Small noncleaved cell lymphoma and leukemia in adults: a retrospective study of 65 adults treated with the LMB pediatric protocols. Blood. 1995;85:664-674.
5. Lee E, Petroni G, Schiffer C, et al. Brief duration high intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 type ALL: results of cancer and leukemia group B study 9251. J Clin Oncol. 2001;19:4014-4022.
6. Atra A, Gerrard M, Hobson R, et al. Outcome of relapsed or refractory childhood B-cell ALL and B-cell NHL treated with the UKCCSG 9003/9002 protocols. Br J Haematol. 2001;112:965-968.
7. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435.
8. Anderson KC, Bates MP, Slaughenhoupt BL, et al. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood. 1984;63:1424-1433.
9. Stashenko P, Nadler LM, Hardy R, et al. Characterization of a human B lymphocyte-specific antigen. J Immunol. 1980;125:1678-1685.
10. Demidem A, Lam T, Alas S, et al. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm. 1997;12:177-186.
11. Corbacioglu S, Eber S, Gungor T, et al. Induction of long-term remission of a relapsed childhood B-ALL with rituximab chimeric anti-CD20 monoclonal antibody and autologous stem cell transplantation. J Pediatr Hematol/Oncol. 2003;25:327-329.
12. Vries MJ, Veerman AJ, Zwaan C. Rituximab in three children with relapsed/refractory B-cell ALL/Burkitt NHL. Br J Haematol. 2004;125:405-417.
13. Culic S, Culic V, Armanda V, et al. Anti-CD20 monoclonal antibody (rituximab) for therapy of mediastinal CD20 positive large B-cell NHL with a local tumor extension into lung of a 10-year-old girl. Pediatr Hematol Oncol. 2003;20:399-344.
14. Ozsahin H, Fluss J, Lin VM, et al. Rituximab with IL-2 after autologous bone marrow transplantation for ALL in second remission. Med Pediatr Oncol. 2002;38:300-301.
15. Heath JA, Broxson EH, Dole MG, et al. EBV associated lymphoma in a child undergoing an autologous stem cell rescue. J Pediatr Hematol/Oncol. 2002;24:160-163.
16. Faye A, Quartier P, Reguerre Y, et al. Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children. Br J Haematol. 2001;115:112-118.
17. Zecca M, Nobili B, Rameghi U, et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood. 2003;101:3857-3861.
18. Cabanillas F, Jagannath S, Philip T, et al. Management of recurrent or refractory NHL. In Magrath IT, ed. The Non-Hodgkin's Lymphomas. 2nd ed. London: Arnold; 1997.
19. Ladenstein R, Pearce R, Hartman O, et al. High-dose chemotherapy with autologous bone marrow rescue in children with poor-risk Burkitt's lymphoma: a report from the European Lymphoma Bone Marrow Transplantation Registry. Blood. 1997;90:2921-2930.
20. Piro LD, White CA, Grillo-Lopez AJ, et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular NHL. Ann Oncol. 1999;10:655-661.
21. Mc Laughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825-2833.
22. Maloney DG, Grillo-Lopez AJ, White GA, et al. IDEC-C2B8(Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade NHL. Blood. 1997;90:2188-2195.
23. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998;92:1927-1932.
24. Rothe A, Schulz H, Elter T, et al. Rituximab monotherapy is effective in patients with poor risk refractory aggressive NHL. Haematologica. 2004;89:875-876.
25. Tobinai K. Clinical trials of a mouse-human chimeric anti-CD20 monoclonal antibody (rituximab) for B cell NHL in Japan. Cancer Chemother Pharmacol. 2001;48(Suppl 1):S85-S90.